等待开盘 08-16 09:30:00 美东时间
-0.110
-1.13%
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**: Mind Medicine (MindMed) 截至2025年6月30日的第二季度财务数据显示,公司持有的现金、现金等价物和投资总额为2.379亿美元。2025年研究与开发(R&D)费用为2980万美元,相较于2024年的1460万美元增加了1520万美元。2025年第二季度的管理与行政(G&A)费用为1110万美元,相较于2024年的980万美元增加了130万美元。</p> <p>• **财务指标变化**: - **现金与投资**:截至2025年6月30日,公司现金、现金等价物和投资总额为2.379亿美元,预
08-12 12:05
Chardan Capital analyst Rudy Li maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $20 price target.
08-01 19:36
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
据知情人士透露,艾伯维正在洽谈收购专注于精神健康治疗的Gilgamesh Pharmaceuticals。如果交易成功,将增强艾伯维在精神疾病治疗方面的产品管线。
07-31 08:52
https://www.foxnews.com/health/key-living-longer-could-tied-surprising-substance-study-suggests
07-16 22:45
Mind Medicine ( ($MNMD) ) has issued an announcement. MindMed has announced the...
07-16 05:08
https://www.bloomberg.com/news/articles/2025-06-30/colorado-moves-to-allow-hallucinogen-ibogaine-for-medical-use?embedded-checkout=true
06-30 23:58
https://www.marijuanamoment.net/rfk-says-trump-administration-could-provide-psychedelic-therapy-to-military-veterans-within-12-months/
06-25 01:44
Most companies operating in the psychedelic medicine space are down significantly after Compass Pathways (NASDAQ:CMPS) on Monday posted late-stage data on its psilocybin-based treatment for treatment-...
06-24 03:24